Francesco De Rubertis

Francesco De Rubertis is a Partner and co-founder of Medicxi, one of the largest Biotech Venture Capital firms in Europe, which was created in January 2016. Having completed his Post Doc at M.I.T. he joined Index Ventures in 1997 to launch the Life Sciences practice. This is where he spearheaded the creation and adoption of the asset-centric investment strategy which had an immediate impact on the success and growth of the firm.

Francesco’s investments include CellZome (acquired by GlaxoSmithKline), Egalet (Nasdaq: EGLT), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (Nasdaq: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, Nasdaq: AFFX), Profibrix (acquired by The Medicines Company).

Francesco received a B.A. in Genetics and Microbiology from the University of Pavia (Italy) and a PhD in Molecular Biology from the University of Geneva (Switzerland) after which he became a postdoctoral scientist at the Whitehead Institute at M.I.T. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva (Switzerland).

In November 2017 Francesco was named in the first “Bloomberg 50” having been nominated, in the Tech & Science sector, as one of the Top 50 entrepreneurs and innovators who helped to define Global Business in 2017. Francesco has served as Board Observer for Xenikos since 2018.